Clinical Trials List
2023-05-26 - 2027-07-31
Phase I/II
Recruiting3
ICD-10C68.9
Malignant neoplasm of urinary organ, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9189.9
Malignant neoplasm of urinary organ, site unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- FU-JEN HSUEH Division of Hematology & Oncology
- Yu-Chieh Tsai Division of Hematology & Oncology
- Yeong-Shiau Pu Division of Urology
- CHUNG-HSIN CHEN Division of Urology
- - - Division of Urology
- 徐偉勛 醫學研究部
- JHE-CYUAN GUO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yuh-Shyan Tsai Division of Urology
- Jiann-Hui Ou Division of Urology
- Che-Yuan Hu Division of Urology
- Wu-Chou Su Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
390 participants
